Eli Lilly & Co will invest $3 billion in China over the next decade to expand local production, with a focus on weight loss https://t.co/fuAzJACnft ...

2026.03. 11 本文字数：1736，阅读时长大约3分钟 作者 | 第一财经 林志吟 继2024年在苏州扩产后，全球减肥药巨头礼来3月11日宣布，计划未来十年累计投资30亿美元全面扩展在华供应链产能，打造口服固体制剂本土生产 与供应体系，着力布局新一代小分子口服GLP-1受体激动剂orforglipron的生产能力。 布局口服减肥药生产 本次扩产针对的药物是orforglipron，后者是礼来拟推向市场的首个口服GLP-1药物。礼来中国已于2025年底向中国药监局提交orforglipron用于治疗2 型糖尿病与肥胖症的上市申请。截至目前，该药还未获批。 凭借在减肥药市场的突出表现，礼来的明星药物GLP-1注射剂替尔泊肽2025年全年销售额达到了365.07亿美元，登上了全球"药王"宝座。 GLP-1已成为降糖减重领域中的革命性靶点，当前，全球GLP-1研发竞赛已进入"下半场"，制药企业正围绕口服小分子、超长效制剂改善患者用药体 验、多靶点激动剂提升疗效、减脂不减肌优化减重质量等方向进行下一代创新减重疗法的研发。 礼来集团副总裁兼中国总经理德赫兰对第一财经记者表示，orforglipron是心血管代谢领 ...

Core Viewpoint - Eli Lilly plans to invest $3 billion over the next decade to expand supply chain capacity in China and build production capacity for type-2 diabetes and obesity treatment orforglipron [1] Group 1: Investment Plans - The company is committing $3 billion for the expansion of its supply chain in China [1] - The investment will focus on increasing production capacity specifically for orforglipron, a treatment for type-2 diabetes and obesity [1] Group 2: Strategic Importance - This move highlights the company's strategy to enhance its operational capabilities in a key market [1] - The investment reflects a growing emphasis on addressing diabetes and obesity, which are significant health concerns globally [1]

Legal & General share price retreated by over 5% on Wednesday, even after the company published strong financial results and a buyback. LGEN dropped to 245p, its lowest level since December last year,... ...

本文源自：金融界AI电报 周二，美国科技股七巨头指数涨0.36%，报195.68点。成分股英伟达收涨1.16%，Meta涨1.03%，亚马 逊、苹果、谷歌A、特斯拉至多涨0.39%，微软则收跌0.89%。此外，AMD收涨0.27%，台积电则收跌 0.46%，伯克希尔哈撒韦B类股跌0.62%，礼来跌0.70%。"超大"市值科技股指数跌0.07%，报372.20点。 除了特斯拉、谷歌A、AMD、苹果、微软、英伟达、Meta Platforms、亚马逊之外，博通收跌0.92%，奈 飞跌1.40%，甲骨文跌1.43%，Salesforce跌1.95%，高通跌2.11%，Adobe跌2.59%。 ...

周二（3月10日），美国科技股七巨头（Magnificent 7）指数涨0.36%，报195.68点。成分股英伟达收涨 1.16%，Meta涨1.03%，亚马逊、苹果、谷歌A、特斯拉至多涨0.39%，微软则收跌0.89%。此外，AMD 收涨0.27%，台积电则收跌0.46%，伯克希尔哈撒韦B类股跌0.62%，礼来跌0.70%。"超大"市值科技股指 数跌0.07%，报372.20点。除了特斯拉、谷歌A、AMD、苹果、微软、英伟达、Meta Platforms、亚马逊 之外，博通收跌0.92%，奈飞跌1.40%，甲骨文跌1.43%，Salesforce跌1.95%，高通跌2.11%，Adobe跌 2.59%。 来源：滚动播报 ...

Core Insights - Eli Lilly and Company (NYSE: LLY) is recognized for its innovative drug development and healthcare solutions, with Bernstein reiterating an "Outperform" rating, indicating confidence in the company's future performance and growth potential [1][6] Investment Activity - The Bank of Montreal Can increased its stake in Eli Lilly by 8.9% during the third quarter, now holding 1,569,917 shares valued at $1.2 billion, which is approximately 0.17% of Eli Lilly's total shares [2][6] - Brighton Jones LLC raised its holdings in Eli Lilly by 22% in the fourth quarter, now owning 9,597 shares valued at $7.4 million, while Revolve Wealth Partners LLC increased its holdings by 2.8%, now possessing 1,471 shares, reflecting a broader trend of investor confidence [3] Stock Performance - Eli Lilly's stock is currently priced at $1,008.39, reflecting an increase of 1.82% or $18.06, with fluctuations between a low of $980.58 and a high of $1,008.86 during the day [4] - Over the past year, Eli Lilly's stock has reached a high of $1,133.95 and a low of $623.78, indicating volatility and potential for growth [4] - The company's market capitalization is approximately $951.27 billion, showcasing its significant presence in the pharmaceutical sector, with a trading volume of 2,016,365 shares on the NYSE [5][6]

Eli Lilly and Company (NYSE:LLY) is one of the top stocks that will make you rich in 10 years. Eli Lilly and Company (LLY) Set to Launch Oral Obesity Drug in Q2, Reuters Reports Reuters reported on March 2 that Eli Lilly and Company (NYSE:LLY) CFO ‌Lucas Montarce stated that the company is making preparations to launch its new oral obesity drug, orforglipron, in the United ​States as early as the second quarter of ​this year once it gets approval from the ⁠Food and Drug Administration. The company furt ...

记者丨韩利明 编辑丨季媛媛 骆一帆 随着跨国药企陆续披露2025年业绩报告，全球制药行业的新一轮竞争格局逐步清晰。 业绩榜单中，强生以全球941.93亿美元的总营收斩获榜首，旗下创新制药和医疗科技两大核心 业务板块分别收入604.01亿美元（+6%）和337.92亿美元（+6.1%）；礼来凭借44%的高增 速，实现651.79亿美元的全年营收，成为增速最快的头部药企。此外，赛诺菲、诺华、阿斯利 康、艾伯维等头部企业营收均保持上升趋势，共同支撑全球制药行业稳步发展。 | | | | | 2025年营收前十跨国药企财务数据(单位:亿美元) | | | | --- | --- | --- | --- | --- | --- | --- | | 排名 | 公司 | 全球总营收 | 同比增速 | 中国区营收 | 同比增速 | 备注 | | 1 | 强生 | 941.93 | 6% | | | | | 2 | 罗氏 | 744. 28 | 7% | 36. 71 | 10% | 全球营收615. 16亿瑞士法郎:中国 区制药业务营收30.34亿瑞士法 郎,按1瑞士法郎=1. 2099美元换算 | | 3 | 礼来 | 6 ...

ab 6 March 2026 Global Research Global Equity Strategy Upgrade Pharma to overweight as a diversifier Many investors are looking for diversifiers amid Middle East tensions. Bonds (as seen during Ukraine or Liberation Day) are not diversifying. This leaves gold (where we are overweight but the 10-year forward inflation breakeven has hardly altered in the past year, suggesting that gold is driven more by geopolitical events than the threat of monetisation of debt), defence stocks (where we are benchmark) and e ...